文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

药物基因组学预测试在临床实践中的实施:现状与展望

Implementation of pre-emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?
PubMed 文献 · Br J Clin Pharmacol · 2023-12-21

药物不良反应在成人住院中占较大比例,在多重疾病患者中更常见。过去十年药物基因组学发展为优化治疗结局的实用工具,部分单基因反应性检测已用于临床,如氟嘧啶类的DPYD检测。从反应性单基因检测向全面预测试基因分型panel的演变具有改进处方的潜力,PREPARE研究首次提供证据表明在七个欧洲医疗系统中预测试药物基因组学panel可行,并使临床相关毒性风险降低30%。

要点

  • DPYD检测用于氟嘧啶类已证明将药物基因组学数据整合到常规护理可经济有效地提高患者安全。
  • PREPARE研究首次证明预测试药物基因组学panel在七个欧洲医疗系统可行,临床相关毒性风险降低30%。
  • 预测试基因分型panel的成本效益、多种合并用药的作用、指南在非欧洲人群的可转移性及罕见变异影响尚待研究。

核心结论

  • 前瞻性应用预测试药物基因组学检测panel在临床实践中可行,PREPARE研究显示临床相关毒性风险降低30%。

研究设计与样本

  • 欧洲PREPARE研究为大型前瞻性随机试验,在七个欧洲医疗系统中实施预测试药物基因组学检测panel。

主要发现

  • PREPARE研究显示预测试药物基因组学检测panel使临床相关毒性风险降低30%。
  • 部分单基因反应性检测已用于临床,如氟嘧啶类的DPYD检测。

关键数值与推荐

  • DPYD检测用于氟嘧啶类,将药物基因组学数据整合到常规护理可经济有效地提高患者安全。
  • PREPARE研究显示预测试药物基因组学检测panel使临床相关毒性风险降低30%。

临床怎么用

  • 可将药物基因组学数据整合到常规护理中以优化治疗结局并降低药物不良反应风险。
  • 从反应性单基因检测向全面预测试基因分型panel演变可改进处方实践。

局限性

  • 预测试基因分型panel的成本效益尚待未来专门研究解决。
  • 多种合并用药的作用尚待未来专门研究解决。
  • 当前测试的药物遗传学指南在非欧洲裔患者中的可转移性尚待未来专门研究解决。
  • 当前基因分型方法未检测到的罕见药物遗传学变异的影响尚待未来专门研究解决。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adverse drug reactions (ADRs) account for a large proportion of hospitalizations among adults and are more common in multimorbid patients, worsening clinical outcomes and burdening healthcare resources. Over the past decade, pharmacogenomics has been developed as a practical tool for optimizing treatment outcomes by mitigating the risk of ADRs. Some single-gene reactive tests are already used in clinical practice, including the DPYD test for fluoropyrimidines, which demonstrates how integrating pharmacogenomic data into routine care can improve patient safety in a cost-effective manner. The evolution from reactive single-gene testing to comprehensive pre-emptive genotyping panels holds great potential for refining drug prescribing practices. Several implementation projects have been conducted to test the feasibility of applying different genetic panels in clinical practice. Recently, the results of a large prospective randomized trial in Europe (the PREPARE study by Ubiquitous Pharmacogenomics consortium) have provided the first evidence that prospective application of a pre-emptive pharmacogenomic test panel in clinical practice, in seven European healthcare systems, is feasible and yielded a 30% reduction in the risk of developing clinically relevant toxicities. Nevertheless, some important questions remain unanswered and will hopefully be addressed by future dedicated studies. These issues include the cost-effectiveness of applying a pre-emptive genotyping panel, the role of multiple co-medications, the transferability of currently tested pharmacogenetic guidelines among patients of non-European origin and the impact of rare pharmacogenetic variants that are not detected by currently used genotyping approaches.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Peruzzi E, Roncato R, De Mattia E, et al. Implementation of pre-emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand? Br J Clin Pharmacol. 2023. PMID: 37926674. doi:10.1111/bcp.15956

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。